References

Global burden of heart failure: a comprehensive and updated review of epidemiology

10.1093/cvr/cvac013 · 2023 · External reference

Global variations in heart failure etiology, management, and outcomes

10.1001/jama.2023.5942 · 2023 · External reference

2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines

10.1016/j.jacc.2021.12.011 · 2022 · External reference

Clinical aspects of hypertensive myocardial fibrosis

10.1097/00001573-200111000-00003 · 2001 · External reference

Drugs of abuse and heart failure

10.1016/j.cardfail.2021.05.023 · 2021 · External reference

Traditional Chinese medicine for cardiovascular disease: evidence and potential mechanisms

10.1016/j.jacc.2017.04.041 · 2017 · External reference

Qishen granules inhibit myocardial inflammation injury through regulating arachidonic acid metabolism

10.1038/srep36949 · 2016 · External reference

Systems-biology dissection of mechanisms and chemical basis of herbal formula in treating chronic myocardial ischemia

10.1016/j.phrs.2016.10.026 · 2016 · External reference

The effects of qishen granules for patients with chronic heart failure: a multicenter randomized double-blind placebo-controlled trial

10.3389/fphar.2022.1017734 · 2022 · External reference

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines

10.1161/hyp.0000000000000066 · 2018 · External reference

N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients

10.1161/01.cir.0000144310.04433.be · 2004 · External reference

Clinical implications of the New York heart association classification

10.1161/jaha.119.014240 · 2019 · External reference

Diagnosis and prevention of hypertensive heart failure

10.1016/j.hfc.2019.05.001 · 2019 · External reference

Hypertension and heart failure: from pathophysiology to treatment

10.3390/ijms25126661 · 2024 · External reference

Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry

10.1016/j.jacc.2018.04.070 · 2018 · External reference

Titration of medical therapy for heart failure with reduced ejection fraction

10.1016/j.jacc.2019.02.015 · 2019 · External reference

The challenges of NT-proBNP testing in HFpEF: shooting arrows in the wind

10.1016/j.jchf.2020.03.003 · 2020 · External reference

Decrease in NTproBNP plasma levels indicates clinical improvement of acute decompensated heart failure

10.1016/j.ajem.2006.08.012 · 2007 · External reference

Comparing New York heart association class and patient-reported outcomes among patients hospitalized for heart failure

10.1161/circheartfailure.122.010107 · 2023 · External reference

Sex differences in New York heart association functional classification and survival in acute heart failure patients with preserved or reduced ejection fraction

10.1016/j.cjca.2019.08.020 · 2020 · External reference

Echocardiographic predictors of cardiovascular outcome in heart failure with preserved ejection fraction

10.1002/ejhf.3271 · 2024 · External reference

Writing up your clinical trial report for a scientific journal: the REPORT trial guide for effective and transparent research reporting without spin

10.1136/bjsports-2021-105058 · 2022 · External reference